GT Biopharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GT Biopharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Apr 16, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Apr 16, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $27.0K | Feb 28, 2018 |
| FY2015 | Dec 31, 2014 | $61.0K | Feb 28, 2018 |
| FY2014 | Dec 31, 2013 | $368.0K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $342.0K | Jan 8, 2015 |
| FY2012 | Dec 31, 2011 | $26.0K | Nov 18, 2014 |
| FY2011 | Dec 31, 2010 | $11.0K | Apr 16, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $27.0K | Feb 28, 2018 |
| FY2015 | Dec 31, 2014 | $4.0K | Feb 28, 2018 |
| FY2014 | Dec 31, 2013 | $142.0K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $248.0K | Jan 8, 2015 |
| FY2012 | Dec 31, 2011 | ($22.0K) | Nov 18, 2014 |
| FY2011 | Dec 31, 2010 | ($54.0K) | Apr 16, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($28.35M) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | $8.30M | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | ($30.17M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($13.16M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($7.60M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($20.88M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($58.01M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($28.30M) | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | ($11.52M) | Apr 16, 2021 |
| FY2020 | Jun 30, 2020 | ($17.42M) | Apr 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.42M) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | ($3.38M) | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | ($1.51M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($14.36M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($13.58M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($21.26M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($57.52M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($6.76M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $16.06M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | ($250.07M) | Mar 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.47M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $5.80M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $6.47M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $8.81M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $9.59M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $485.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.67M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | $9.07M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.07M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $975.0K | Mar 1, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.95M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $8.57M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $7.11M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $12.45M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $47.92M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.28M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $9.79M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | $12.49M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $134.50M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $8.40M | Mar 1, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.91M) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | ($8.89M) | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | ($5.22M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($12.90M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($8.85M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($15.22M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($15.61M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($7.26M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($3.66M) | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | ($10.68M) | Mar 27, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | Mar 27, 2020 |
| FY2019 | Dec 31, 2018 | $36.0K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $4.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $1.0K | Feb 28, 2018 |
| FY2015 | Dec 31, 2014 | $6.0K | Feb 28, 2018 |
| FY2014 | Dec 31, 2013 | $0 | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $2.0K | Jan 8, 2015 |
| FY2012 | Dec 31, 2011 | $0 | Nov 18, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.11M | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | $4.32M | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | $7.12M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $4.23M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $14.11M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $16.74M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $32.17M | Mar 30, 2023 |
| FY2020 | Dec 31, 2020 | $5.66M | Apr 16, 2021 |
| FY2020 | Dec 31, 2019 | $396.0K | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | $25.40M | Mar 27, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.32M | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | $31.04M | Mar 2, 2026 |
| FY2023 | Dec 31, 2023 | $6.63M | Mar 26, 2024 |
| FY2023 | Dec 31, 2022 | $5.00M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $10.26M | Mar 30, 2023 |
| FY2019 | Dec 31, 2019 | $19.71M | Mar 27, 2020 |
| FY2019 | Dec 31, 2018 | $14.03M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.68M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $18.95M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $50.62M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.79M | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | $3.00M | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | ($25.88M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($1.67M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $7.48M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $11.73M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $21.91M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | ($29.43M) | Mar 30, 2023 |
| FY2020 | Sep 30, 2020 | ($29.78M) | Apr 16, 2021 |
| FY2020 | Jun 30, 2020 | ($27.50M) | Apr 16, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($723.90M) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | ($718.10M) | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | ($726.26M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($695.23M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($682.07M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($674.47M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($653.58M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($595.80M) | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | ($589.34M) | Apr 16, 2021 |
| FY2020 | Jun 30, 2020 | ($586.46M) | Apr 16, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.81M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.95M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.08M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $5.67M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $8.97M | Mar 30, 2023 |
| FY2020 | Dec 31, 2020 | $5.30M | Apr 16, 2021 |
| FY2020 | Dec 31, 2019 | $28.0K | Apr 16, 2021 |
| FY2020 | Dec 31, 2018 | $60.0K | Apr 16, 2021 |
| FY2019 | Dec 31, 2017 | $576.0K | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $19.0K | Mar 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | (10) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | (19) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2018 | Dec 31, 2018 | (5) | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | (8) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 119 | Mar 1, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | (10) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | (19) | Mar 26, 2024 |
| FY2018 | Dec 31, 2018 | (5) | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | (8) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 119 | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | (8) | Feb 28, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.53M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 2.23M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 1.38M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 1.09M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 32.06M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 5.22M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 4.10M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | 50.65M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 50.12M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 104,218 | Mar 1, 2018 |